9th Circ. Refuses To Revive Novartis Jaw Injury Suit
Law360, Los Angeles (February 20, 2014, 10:34 PM EST) -- A Ninth Circuit panel on Thursday refused to revive a product liability lawsuit against Novartis Pharmaceuticals Corp. over jaw injuries allegedly related to bone drugs Aredia and Zometa, ruling that the plaintiff continued the drugs after his injury and could not prove they caused it.
In a memorandum opinion, the court affirmed a lower court’s grant of summary judgment to Novartis because plaintiff Duane Luttrell could not prove the drugs were the proximate cause of his jaw’s osteonecrosis.
Luttrell claimed Novartis did not provide proper warning for the drugs, and needed to show that his doctor would have made different choices...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!